

**INFORMATION
DISCLOSURE
STATEMENT BY APPLICANT**

| | | | |
|-------|---|----|---|
| Sheet | 1 | of | 2 |
|-------|---|----|---|

| | |
|--------------------|------------|
| Application Number | 09/771,302 |
|--------------------|------------|

| | |
|-------------|------------------|
| Filing Date | January 26, 2001 |
|-------------|------------------|

| | |
|----------------------|------------|
| First Named Inventor | Whitehouse |
|----------------------|------------|

| | |
|----------------|-----------------------------|
| Group Art Unit | Not yet assigned |
|----------------|-----------------------------|

| | |
|---------------|-----------------------------|
| Examiner Name | Not yet assigned |
|---------------|-----------------------------|

| | |
|------------------------|---------------------|
| Attorney Docket Number | 1543.201 (5784-81A) |
|------------------------|---------------------|

| Examiner Initials* | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant Of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear |
|-----------------------|--------------------------|----------------------|--------------------------------------|---|---|---|
| | | Number | Kind Code ² (if known) | | | |
| | | | | | | |

[illegible][illegible]

Examiner
Signature


Date
Considered

11/12/02

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

⁶ Applicant is to place a check mark here if English language Translation is attached.

PAPER NO. 3



| | | | | | |
|---|----------------|---|---|--------------------------|---------------------|
| Substitute for form 1449A/PTO | | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Application Number | 09/771,302 |
| | | | | Filing Date | January 26, 2001 |
| | | | | First Named Inventor | Whitehouse |
| | | | | Group Art Unit | Not yet assigned |
| | | | | Examiner Name | Not yet assigned |
| Sheet | 5 | of | 5 | Attorney Docket Number | 1543.201 (5784-81A) |
| NON PATENT LITERATURE DOCUMENTS (Continued) | | | | | |
| RWJ | 81 | XIAO <i>et al.</i> (1996), "Efficient Long-Term Gene Transfer into Muscle Tissue of Immunocompetent Mice by Adeno-Associated Virus Vector," <i>Journal of Virology</i> 70: 8098-8108. | | | |
| | 82 | YANAGISAWA-MIWA <i>et al.</i> (1992), "Salvage of Infarcted Myocardium by Angiogenic Action of Basic Fibroblast Growth Factor," <i>Science</i> 257: 1401-1403. | | | |
| | 83 | YAYON <i>et al.</i> (1990), "Autocrine Regulation of Cell Growth and Transformation by Basic Fibroblast Growth Factor," <i>Cancer and Metastasis Reviews</i> 9: 191-202. | | | |
| Examiner Signature | Hegna M. DeBry | | | Date Considered | 5/2/03 |

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RTA01/2094354v1

paper no. 3


**INFORMATION
DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

| | | | | | |
|-------|---|----|---|------------------------|---------------------|
| Sheet | 4 | of | 5 | Application Number | 09/771,302 |
| | | | | Filing Date | January 26, 2001 |
| | | | | First Named Inventor | Whitehouse |
| | | | | Group Art Unit | Not yet assigned |
| | | | | Examiner Name | Not yet assigned |
| | | | | Attorney Docket Number | 1543.201 (5784-81A) |

NON PATENT LITERATURE DOCUMENTS (Continued)

| | |
|----|--|
| 62 | NABEL <i>et al.</i> (1993), "Recombinant Fibroblast Growth Factor-1 Promotes Intimal Hyperplasia and Angiogenesis in Arteries <i>In Vivo</i> ," <i>Nature</i> 362: 844-846. |
| 63 | NAHREINEI <i>et al.</i> (1993), "Versatile Adeno-Associated Virus 2-Based Vectors for Construction Recombinant Virions," <i>Gene</i> 124: 257-262. |
| 64 | OHNO <i>et al.</i> (1994), "Gene Therapy for Vascular Smooth Muscle Cell Proliferation After Arterial Injury," <i>Science</i> 265: 781-784. |
| 65 | ORKIN <i>et al.</i> (December 7, 1995), "Report and Recommendations of the Panel to Assess the HIB Investment in Research on Gene Therapy," 41 pages. |
| 66 | ORNITZ <i>et al.</i> (1996), "Receptor Specificity of the Fibroblast Growth Factor Family," <i>J. Biol. Chem.</i> 271: 15292-15297. |
| 67 | RAKUSAN (1995), "Coronary Angiogenesis," <i>Annals New York Academy of Sciences</i> 752: 257-265. |
| 68 | RUBIN <i>et al.</i> (1989), "Purification and Characterization of a Newly Identified Growth Factor Specific for Epithelial Cells," <i>Proc. Natl. Acad. Sci. USA</i> 86: 802-806. |
| 69 | SCHUBERT <i>et al.</i> (1987), "Multiple Influences of a Heparin-Binding Growth Factor on Neuronal Development," <i>The Journal of Cell Biology</i> 104: 635-643. |
| 70 | SCHUMACHER <i>et al.</i> (1997), "Induction of Neoangiogenesis in Ischemic Myocardium by Human Growth Factors," <i>Circulation</i> 97: 645-650. |
| 71 | SELLKE <i>et al.</i> (1994), "Basic FGF Enhances Endothelium-Dependent Relaxation of the Collateral-Perfused Coronary Microcirculation," <i>The American Physiological Society</i> 267: H1303-H1311. |
| 72 | SELLKE <i>et al.</i> (1996), "Enhanced Microvascular Relaxations to VEGF and bFGF in Chronically Ischemic Porcine Myocardium," <i>Am. J. Physiol.</i> 271: H713-H720. |
| 73 | SELLKE <i>et al.</i> (1996), "Angiogenesis Induced by Acidic Fibroblast Growth Factor as an Alternative Method of Revascularization for Chronic Myocardial Ischemia," <i>Surgery</i> 120: 182-188. |
| 74 | SELLKE <i>et al.</i> (1998), "Therapeutic Angiogenesis with Basic Fibroblast Growth Factor: Technique and Early Results," <i>The Society of Thoracic Surgeons</i> 65: 1540-1544. |
| 75 | SHOU <i>et al.</i> (1997), "Effect of Basic Fibroblast Growth Factor on Myocardial Angiogenesis in Dogs with Mature Collateral Vessels," <i>JACC</i> 29: 1102-1106. |
| 76 | SLAVIN (1995), "Fibroblast Growth Factors: At the Heart of Angiogenesis," <i>Cell Biology International</i> 19: 431-444. |
| 77 | UCHIDA <i>et al.</i> (1995), "Angiogenic Therapy of Acute Myocardial Infarction by Intrapericardial Injection of Basic Fibroblast Growth Factor and Heparin Sulfate: An Experimental Study," <i>American Heart Journal</i> 130: 1182-1188. |
| 78 | UNGER <i>et al.</i> (1994), "Basic Fibroblast Growth Factor Enhances Myocardial Collateral Flow in a Canine Model," <i>Am. J. Physiol</i> 266: H1588-H1595. |
| 79 | VALLES <i>et al.</i> (1990), "Acidic Fibroblast Growth Factor is a Modulator of Epithelial Plasticity in a Rat Bladder Carcinoma Cell Line," <i>Proc. Natl. Acad. Sci. USA</i> 87: 1124-1128. |
| 80 | WATANABE <i>et al.</i> (1998), "Effect of Basic Fibroblast Growth Factor on Angiogenesis in the Infarcted Porcine Heart," <i>Basic Res. Cardiol.</i> 93: 30-37. |



Substitute for form 1449A/PTO

**INFORMATION
DISCLOSURE****STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 5

Complete if Known


| | |
|------------------------|---------------------------|
| Application Number | 09/771,302 |
| Filing Date | January 26, 2001 |
| First Named Inventor | Whitehouse |
| Group Art Unit | Not yet assigned 11047 |
| Examiner Name | Not yet assigned J. Berry |
| Attorney Docket Number | 1543.201 (5784-81A) |

U. S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant Of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear |
|-----------------------|--------------------------|----------------------|--------------------------------------|---|--|---|
| | | Number | Kind Code ² (if known) | | | |
| RM | 1 | 4,296,100 | | Franco | 10-20-1981 | |
| | 2 | 4,378,347 | | Franco | 03-29-1983 | |
| | 3 | 4,956,455 | | Esch <i>et al.</i> | 09-11-1990 | |
| | 4 | 5,137,510 | | VanDeripe | 08-11-1992 | |
| | 5 | 5,137,734 | | Spiegelman <i>et al.</i> | 08-11-1992 | |
| | 6 | 5,155,214 | | Baird <i>et al.</i> | 10-13-1992 | |
| | 7 | 5,155,217 | | Goldfarb <i>et al.</i> | 10-13-1992 | |
| | 8 | 5,213,570 | | VanDeripe | 05-25-1993 | |
| | 9 | 5,238,916 | | Goldfarb <i>et al.</i> | 08-24-1993 | |
| | 10 | 5,244,460 | | Unger <i>et al.</i> | 09-14-1993 | |
| | 11 | 5,269,326 | | Verrier | 12-14-1993 | |
| | 12 | 5,302,702 | | Seddon <i>et al.</i> | 04-12-1994 | |
| | 13 | 5,310,883 | | Seddon <i>et al.</i> | 05-10-1994 | |
| | 14 | 5,352,589 | | Bergonzoni <i>et al.</i> | 10-04-1994 | |
| | 15 | 5,371,206 | | Seddon <i>et al.</i> | 12-06-1994 | |
| | 16 | 5,387,673 | | Seddon <i>et al.</i> | 02-07-1995 | |
| | 17 | 5,439,818 | | Fiddes <i>et al.</i> | 08-08-1995 | |
| | 18 | 5,464,774 | | Baird <i>et al.</i> | 11-07-1995 | |
| | 19 | 5,491,220 | | Seddon <i>et al.</i> | 02-13-1996 | |
| | 20 | 5,514,566 | | Fiddes <i>et al.</i> | 05-07-1996 | |
| | 21 | 5,604,293 | | Fiddes <i>et al.</i> | 02-18-1997 | |
| | 22 | 5,750,659 | | Basilico <i>et al.</i> | 05-12-1998 | |
| | 23 | 5,792,453 | | Hammond <i>et al.</i> | 08-11-1998 | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

¹ Unique citation designation number.² See attached Kinds of U.S. Patent Documents.

paper no. 3



Substitute for form 1449A/PTO

Complete if Known

INFORMATION
DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 2

| | |
|------------------------|--------------------------|
| Application Number | 09/771,302 |
| Filing Date | January 26, 2001 |
| First Named Inventor | Whitehouse |
| Group Art Unit | Not yet assigned 1647 |
| Examiner Name | Not yet assigned DeBerry |
| Attorney Docket Number | 1543.201 (5784-81A) |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T |
|--------------------|------------|---|--------------------------|
| RM | 88 | BENJAMIN <i>et al.</i> (1998) "A Plasticity Window for Blood Vessel Remodelling is Defined by Pericyte Coverage of the Preformed Endothelial Network and is Regulated by PDGF-B and VEGF," <i>Development</i> 125: 1591-1598. | |
| | 89 | BORK <i>et al.</i> (1996) "Go Hunting in Sequence Databases but Watch Out for the Traps," <i>Trends in Genetics</i> 12: 425-427. | |
| | 90 | BORK (2000) "Powers and Pitfalls in Sequence Analysis: The 70% Hurdle," <i>Genome Research</i> 10: 398-400. | |
| | 91 | BRENNER (1999) "Errors in Genome Annotation," <i>Trends in Genetics</i> 15: 132-133. | |
| | 92 | DOERKS <i>et al.</i> (1998) "Protein Annotation: Detective Work for Function Prediction," <i>Trends in Genetics</i> 14: 248-250. | |
| | 93 | GALZIE <i>et al.</i> (1997) "Fibroblast Growth Factors and Their Receptors," <i>Biochem. Cell. Biol.</i> 75: 669-685. | |
| | 94 | ISNER (1996) "The Role of Angiogenic Cytokines in Cardiovascular Disease," <i>Clinical Immunology and Immunopathology</i> 80: S82-S91. | |
| | 95 | MASSAGUE <i>et al.</i> (1987) "The TGF-beta Family of Growth and Differentiation Factors," <i>Cell</i> 49: 437-438. | |
| | 96 | NGO <i>et al.</i> (1994) "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," <i>The Protein Folding Problem and Tertiary Structure Prediction</i> , pp. 492-495. | |
| | 97 | PILBEAM <i>et al.</i> (1993) "Comparison of the Effects of Various Lengths of Synthetic Human Parathyroid Hormone - Related Peptide (hPTHrP) of Malignancy on Bone Resorption and formation in Organ Culture," <i>Bone</i> 14: 717-720. | |
| RM | 98 | SKOLNICK <i>et al.</i> (2000) "From Genes to Protein Structure and Function: Novel Applications of Computational Approaches in the Genomic Era," <i>Trends in Biotech</i> 18: 34-39. | |
| | 99 | SMITH <i>et al.</i> (1997) "The Challenges of Genome Sequence Annotation or 'The Devil is in the Details'," <i>Nature Biotech</i> 15: 1222-1223. | |
| | 100 | VUKICEVIC <i>et al.</i> (1996) "Induction of Nephrogenic Mesenchyme by Osteogenic Protein 1 (Bone Morphogenetic Protein 7)," <i>Proc. Natl. Acad. Sci. USA</i> 93: 9021-9026. | |
| | 101 | WELLS (1990) "Additivity of Mutational Effects in Proteins," <i>Biochemistry</i> 29: 8509-8517. | |
| Examiner Signature | RM DeBerry | | Date Considered 11/18/02 |

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 5

Complete if Known

| | | | |
|------------------------|--|---------------------|--|
| Application Number | | 09/771,302 | |
| Filing Date | | January 26, 2001 | |
| First Named Inventor | | Whitehouse | |
| Group Art Unit | | Not yet assigned | |
| Examiner Name | | Not yet assigned | |
| Attorney Docket Number | | 1543.201 (5784-81A) | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials | Cite No. | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|-------------------|----------|-------------------------|---------------------|-----------------------------------|---|---|---|----------------|
| | | Office ³ | Number ⁴ | Kind Code (if known) ⁵ | | | | |
| RW | 24 | EP | 0 228 449 | B1 | Esch <i>et al.</i> | 07-15-1987 | | |
| JK | 25 | WO | 89/04832 | A1 | Arakawa <i>et al.</i> | 06-01-1989 | | |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T |
|-------------------|----------|---|---|
| AK | 26 | ABRAHAM <i>et al.</i> (1986), "Human Basic Fibroblast Growth Factor: Nucleotide Sequence and Genomic Organization," <i>The EMBO Journal</i> 5: 2523-2528. | |
| | 27 | ANDERSON (1994), "Gene Therapy for Genetic Diseases," <i>Human Gene Therapy</i> 5: 281-282. | |
| | 28 | BANAI <i>et al.</i> (1994), "Angiogenic-Induced Enhancement of Collateral Blood Flow to Ischemic Myocardium by Vascular Endothelial Growth Factor in Dogs," <i>Circulation</i> 89: 2183-2189. | |
| | 29 | BARINAGA (1994), "Step Taken Toward Improved Vectors for Gene Transfer," <i>Science</i> 266: 1326. | |
| | 30 | BARR (1994), "Efficient Catheter-Mediated Gene Transfer into the Heart Using Replication-Defective Adenovirus," <i>Gene Therapy</i> 1: 51-58. | |
| | 31 | BATTLER <i>et al.</i> (1993), "Intracoronary Injection of Basic Fibroblast Growth Factor Enhances Angiogenesis in Infarcted Swine Myocardium," <i>JACC</i> 22: 2001-2006. | |
| | 32 | BIKFALVI <i>et al.</i> (1997), "Biological Roles of Fibroblast Growth Factor-2," <i>Endocrine Reviews</i> 18: 26-45. | |
| | 33 | BROWN (1995), "Gene Therapy 'Oversold' by Researchers, Journalists," <i>The Washington Post</i> : A1 and A22. | |
| | 34 | BURGESS <i>et al.</i> (1989), "The Heparin-Binding (Fibroblast) Growth Factor Family of Proteins," <i>Annu. Rev. Biochem.</i> 58: 575-606. | |
| | 35 | CHALLITA <i>et al.</i> (1994), "Lack of Expression from a Retroviral Vector After Transduction of Murine Hematopoietic Stem Cells is Associated with Methylation <i>in vivo</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 91: 2567-2571. | |
| | 36 | CLEMENTS <i>et al.</i> (1993), "Activation of Fibroblast Growth Factor (FGF) Receptors by Recombinant Human FGF-5," <i>Oncogene</i> 8: 1311-1316. | |
| | 37 | COGHLAN (1995), "Gene Dream Fades Away," <i>New Scientist</i> 148: 14-15. | |
| | 38 | CORALLINI <i>et al.</i> (1996), "Promotion of Tumour Metastases and Induction of Angiogenesis by Native HIV-1 Tat Protein from BK Virus/Tat Transgenic Mice," <i>AIDS</i> 10: 701-710. | |
| | 39 | COULIER <i>et al.</i> (1991), "Putative Structure of the <i>FGF6</i> Gene Product and Role of the Signal Peptide," <i>Oncogene</i> 6: 1437-1444. | |
| | 40 | FISHER <i>et al.</i> (1997), "Recombinant Adeno-Associated Virus for Muscle Directed Gene Therapy," <i>Nature Medicine</i> 3: 306-312. | |
| JK | 41 | FOLKMAN (1998), "Angiogenic Therapy of the Human Heart," <i>Circulation</i> 97: 628-629. | |

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible.

⁶ Applicant is to place a check mark here if English language Translation is attached.

paper NO: 3

Substitute for form 1449A/PTO

APR 16 2001

Complete if Known

**INFORMATION
DISCLOSURE & TRADEMARK OFFICE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

3

of

5

Application Number

09/771,302

Filing Date

January 26, 2001

First Named Inventor

Whitehouse

Group Art Unit

Not yet assigned

Examiner Name

Not yet assigned

Attorney Docket Number

1543.201 (5784-81A)

NON PATENT LITERATURE DOCUMENTS (Continued)

| | | |
|----|--|---|
| 42 | GIORDANO <i>et al.</i> (1995), "Reduced Myocardial Ischemia after Recombinant Adenovirus Mediated <i>In-Vivo</i> Fibroblast Growth Factor-5 Gene Transfer," <i>J. Invest. Med.</i> 3: 278A. | |
| 43 | GIORDANO <i>et al.</i> (1996), "Intracoronary Gene Transfer of Fibroblast Growth Factor-5 Increases Blood Flow and Contractile Function in an Ischemic Region of the Heart," <i>Nature Medicine</i> 2: 534-539. | |
| 44 | GUZMAN <i>et al.</i> (1993), "Efficient Gene Transfer into Myocardium by Direct Injection of Adenovirus Vectors," <i>Circulation Research</i> 73: 1202-1207. | |
| 45 | HARADA <i>et al.</i> (1994), "Basic Fibroblast Growth Factor Improves Myocardial Function in Chronically Ischemic Porcine Hearts," <i>J. Clin. Invest.</i> 94: 623-630. | |
| 46 | JAROFF (1996), "Keys to the Kingdom," <i>Time</i> 148: 24-29. | |
| 47 | KASS-EISLER <i>et al.</i> (1993), "Quantitative Determination of Adenovirus-Mediated Gene Delivery to Rat Cardiac Myocytes <i>in vitro</i> and <i>in vivo</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 90: 11498-11502. | |
| 48 | KIRSCHNER <i>et al.</i> (1995), "Basic Fibroblast Growth Factor Protects Against Excitotoxicity and Chemical Hypoxia in Both Neonatal and Adult Rats," <i>J. Cerebral Blood Flow and Metabolism</i> 15: 619-623. | |
| 49 | KLAGSBRUN (1991), "Angiogenic Factors: Regulators of Blood Supply-Side Biology," <i>The New Biologist</i> 3: 745-749. | |
| 50 | LAHAM <i>et al.</i> (1998), "Local Perivascular Basic Fibroblast Growth Factor (bFGF) Treatment in Patients with Ischemic Heart Disease," <i>J. Am. Coll. Cardiol.</i> 31: 394A. | ✓ |
| 51 | LAHAM <i>et al.</i> (2000), "Intrapericardial Delivery of Fibroblast Growth Factor-2 Induces Neovascularization in a Porcine Model of Chronic Myocardial Ischemia," <i>The Journal of Pharmacology and Experimental Therapeutics</i> 292: 795-802. | |
| 52 | LANDAU <i>et al.</i> (1995), "Intrapericardial Basic Fibroblast Growth Factor Induces Myocardial Angiogenesis in a Rabbit Model of Chronic Ischemia," <i>American Heart Journal</i> 129: 924-931. | |
| 53 | LAZAROUS <i>et al.</i> (1996), "Comparative Effects of Basic Fibroblast Growth Factor and Vascular Endothelial Growth Factor on Coronary Collateral Development and the Arterial Response to Injury," <i>Circulation</i> 94: 1075-1082. | |
| 54 | LAZAROUS <i>et al.</i> (1995), "Effects of Chronic Systemic Administration of Basic Fibroblast Growth Factor on Collateral Development in the Canine Heart," <i>Circulation</i> 91: 145-153. | |
| 55 | LIPTON <i>et al.</i> (1988), "Acidic Fibroblast Growth Factor Enhances Regeneration of Processes by Postnatal Mammalian Retinal Ganglion Cells in Culture," <i>Proc. Natl. Acad. Sci., USA</i> 85: 2388-2392. | |
| 56 | LOPEZ <i>et al.</i> (1996), "Local Perivascular Administration of Basic Fibroblast Growth Factor: Drug Delivery and Toxicological Evaluation," <i>Drug and Metabolism and Disposition</i> 24: 922-924. | |
| 57 | MAGOVERN <i>et al.</i> (1996), "Direct <i>in vivo</i> Gene Transfer to Canine Myocardium Using a Replication-Deficient Adenovirus Vector," <i>Ann. Thorac. Surg.</i> 62: 425-434. | |
| 58 | MARSHALL (1995), "Gene Therapy's Growing Pains," <i>Science</i> 269: 1050-1055. | |
| 59 | MATHIEU <i>et al.</i> (1995), "Receptor Binding and Mitogenic Properties of Mouse Fibroblast Growth Factor 3," <i>the Journal of Biological Chemistry</i> 270: 24197-24203. | |
| 60 | MIYAMOTO <i>et al.</i> (1993), "Molecular Cloning of a Novel Cytokine cDNA Encoding the Ninth Member of the Fibroblast Growth Factor Family, Which Has a Unique Secretion Property," <i>Molecular and Cellular Biology</i> 13: 4251-4259. | |
| 61 | MIYATAKA <i>et al.</i> (1998), "Basic Fibroblast Growth Factor Increased Regional Myocardial Blood Flow and Limited Infarct Size of Acutely Infarcted Myocardium in Dogs," <i>Angiology</i> 49: 381-390. | |

paper NO: 3